JOOTRH Receives Major Boost for Prostate Cancer Care

JOOTRH Receives Major Boost for Prostate Cancer Care

By Sherine Atieno                                                                                                                                                                     Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) has taken a significant step forward in its fight against cancer. Thanks to a generous donation from Cancer Care Africa (CCA) through the East Africa Microbiology Laboratory, the hospital has received a new Prostate-Specific Antigen (PSA) machine and 1,000 test kits for prostate cancer screening.

This critical contribution will significantly enhance JOOTRH’s diagnostic capabilities and provide advanced prostate cancer screening to a wider range of patients.

A recent meeting at the JOOTRH boardroom brought together key stakeholders to celebrate this milestone. Dr. Richard Lesiyampe (CEO), Dr. Joshua Okise (DFA), Stephen Onduo (Procurement), Dr. Iyenya Allan (Urologist Surgeon), Dr. Hezron Okoth (Laboratory In-charge), Dr. Cosmas Ngisa (Nursing Officer, Consultant Clinic), and Justus… were all present.

Boosting Accessibility and Saving Lives

The donation represents a major step forward in JOOTRH’s mission to provide accessible and advanced healthcare. Previously, the high cost of PSA testing (approximately 2,500 Kenyan shillings) created a significant barrier for many patients, particularly those facing financial hardship.

With this donation, up to 1,000 patients will now be able to receive free, advanced prostate cancer screening, significantly improving their access to essential healthcare.

This isn’t the first time CCA has supported JOOTRH. The East Africa Microbiology Laboratory previously donated an ultrasound machine, currently benefiting 80% of patients who require its services. The success of the ultrasound machine highlights the expected impact of the PSA machine and test kits.

Early Detection, Improved Outcomes

The availability of these resources will not only enable early detection and treatment of prostate cancer but also promote a culture of preventive healthcare. Early screening is critical for effective management and treatment, potentially saving lives and improving the quality of life for many patients. Easier access to these tools will encourage more men to undergo screening, leading to earlier diagnoses and better treatment options.

Collaboration is Key

This donation underscores the importance of partnerships in healthcare. The involvement of organizations like CCA highlights a commendable commitment to improving healthcare outcomes. It also recognizes JOOTRH’s role as a regional leader, capable of leveraging such partnerships to bring advanced medical technologies to the community.

A Milestone Achieved

JOOTRH has reached a significant milestone in its fight against cancer. The new PSA machine and test kits will improve prostate cancer screening and treatment accessibility, ultimately leading to better health outcomes and easing financial burdens for patients. This is a victory not just for JOOTRH, but for countless patients who will now benefit from these advanced medical resources.

Leave a Reply

Your email address will not be published.